Clinical Trial Update: A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 safety and efficacy study of hu14 for high-risk neuroblastoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• hu14

Snippet

Sponsor: Renaissance Pharma Ltd. | Conditions: High-Risk Neuroblastoma | Phase 2, Phase 3 | Status: RECRUITING